Forget JEPI, Goldman’s Income Beat Has Surged Since Launch
A new income-focused ETF challenger has pushed past JEPI by roughly 42 percentage points since its October 2023 debut...
User Friendly Crypto Exchanges 2023
Choosing a user-friendly crypto exchange is essential for smooth trading. Check out our list of the best options available in 2023.
10,063 articlesMeta Wants Cloud: Is Amazon Stock Still a Buy?
Meta wants cloud could shake up the cloud market and test Amazon's AWS dominance. This guide breaks down what that co...
Gap’s Dividend Scorecard: Does Selloff Change Income Case
Gap reported a Q4 beat on earnings but a sharp post-earnings slide as margins face tariff pressure. The company raise...
Pfizer Just Locked Next Growth Path: What Investors Should Know
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
Arbe (arbe) 2025 Earnings Outlook for Investors
This guide dives into Arbe's Q2 2025 earnings, decoding revenue growth, margins, and guidance. Learn actionable ways ...
AI’s Productivity Gains Years Away, Markets Brace for Debts
A top Deutsche Bank economist warns that AI’s productivity gains may take years to materialize. If returns lag, risin...
Tesla Loses California License Push Over Autopilot Terms
California regulators said Tesla will not face a 30-day suspension after dropping marketing terms tied to its driver-...
Is Marvell Finally Narrowing the Broadcom-AI Revenue Gap?
Marvell Technology shows signs of narrowing Broadcom's AI revenue lead as data-center demand accelerates, sparking re...
Wiping Entry-Level Jobs. Here’s How Colleges Adapt
AI reshapes entry-level work as automation accelerates, pushing colleges to rethink internships and hands-on experien...
America Just Committed $1.2 Trillion: A Blind Bet on Roads
The U.S. pledged a historic $1.2 trillion to fix aging infrastructure, but experts warn that funding alone won’t prev...
Starboard’s Dynatrace Play: Activist Turnaround or Sale
Starboard Value’s effort at Dynatrace tests whether the observability software maker can turn around on its own or be...
Should Shares CRISPR Therapeutics Be a February Pick?
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status